CEXAL LTD develops novel biosensor technology for rapid, point-of-need molecular diagnostics. Their proprietary assays deliver definitive results comparable to laboratory methods in under 30 minutes for bacterial detection and small-molecule analysis. The technology supports applications across infectious disease monitoring, environmental testing, and industrial screening.
Funding
Funding not disclosed
Founders
Product
Problem
Current microbial detection methods often require extensive laboratory infrastructure and significant processing time, delaying critical diagnostic insights. This delay can impede timely intervention in clinical settings and slow down environmental monitoring processes.
Solution
CEXAL LTD develops rapid molecular diagnostic assays that deliver definitive results for biomarkers and bacteria in under 30 minutes. The company's proprietary biosensor technology facilitates point-of-need testing directly on clinical or environmental samples, bypassing the need for complex laboratory equipment. This approach enables faster identification of microbial targets and their characteristics, such as antibiotic susceptibility, directly at the site of sample collection. The platform is designed for ease of use, providing laboratory-grade accuracy in a significantly reduced timeframe.
Target Audience
The primary customers are clinical laboratories, healthcare providers, and environmental monitoring agencies that require fast and accurate microbial diagnostic capabilities.
Features
- Proprietary biosensor technology for rapid molecular detection of biomarkers and bacteria.
- Point-of-need testing capability directly on clinical or environmental samples.
- Assay turnaround time of under 30 minutes for bacterial identification and antibiotic susceptibility testing.
- Minimal external equipment requirement for most testing scenarios.
- Two-probe DNA assay design for targeted detection.
- FluoCDx Platform for bacterial detection in 5 minutes and antibiotic susceptibility testing in 30 minutes.